ASYMMETRYBETA
Loading LLY...
Eli Lilly & CoLLYAs of 31 July 2026
Trailing (TTM)
Price to earnings·
Price to sales·
Price to book·
Price to op. cash flow·
Price to free cash flow·
Forward P/S (NTM)
Forward P/S (Y1)·
Forward P/S (Y2)·
Forward P/S (Y3)·
Forward P/S (Y4)·
Forward P/S (Y5)·
Forward P/E (NTM)
Forward P/E (Y1)·
Forward P/E (Y2)·
Forward P/E (Y3)·
Forward P/E (Y4)·
Forward P/E (Y5)·
Forward EV/EBIT (NTM)
Forward EV/EBIT (Y1)·
Forward EV/EBIT (Y2)·
Forward EV/EBIT (Y3)·
Forward EV/EBIT (Y4)·
Forward EV/EBIT (Y5)·
−300−1500+150+300
−70
PositiveNegative
Positive skew
Valuation+13
CheapExpensive
Emotion−9
FearGreed
Fundamentals+74
WeakStrong
Valuation

Is Eli Lilly & Co undervalued or overvalued?

Where Eli Lilly & Co (LLY) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.

Eli Lilly & CoLLYLast 5 years
V—E—F—A—
——
LLY priceasymmetryquant.com
A Asymmetry—
V Valuation—
E Emotion—
F Fundamentals—